Fig. 3
From: Phase I dose-escalation oncology trials with sequential multiple schedules
Misspecification of elimination half-life Te and different timing of DLT. Using different values of Te, posterior median, 50% and 95% equi-tailed credible intervals for end-of-cycle 1 DLT probabilities obtained by TITE-PK for two hypothetical datasets (early DLT and late DLT) and the original everolimus trial dataset are shown. Early DLT dataset and late DLT dataset are created by changing timing of DLT from day 15 to day 1.5 and to day 20.5, respectively. Data from both weekly and daily schedules are included in the analysis